TABLE 1.
Daily doses of sustained-release morphine and quantitative study measures across study stages for the two super-responders identified through the semistructured interviews
| Participant 1 # | Participant 2 ¶ | |||||||
| Baseline | Week 1 | Week 3 | 6 months | Baseline | Week 1 | Week 3 | 6 months | |
| SR morphine daily dose, mg | 16 | 16 | 16 | 8 | 24 | 24 | ||
| NRS breathlessness, 0–10 points | ||||||||
| Worst | 6.5 | 3.7 | 0.3 | 1 | 5 | 6 | 6.6 | 6 |
| Average | 3 | 3.3 | 0.3 | 1 | 3.5 | 3.6 | 4.3 | 4 |
| Unpleasantness | 6 | 2.3 | 0 | 1 | 2 | 1 | 1 | 1 |
| mMRC | 3 | 3 | 1 | 3 | 2 | 2 | ||
| CRQ | ||||||||
| Dyspnoea | 4.25 | 5.4 | 6 | 2.8 | 5 | 5 | ||
| Mastery | 4 | 6.25 | 6.25 | 5.75 | 5.75 | 5.75 | ||
| FitBit data + , average per day | ||||||||
| Caloric expediture, kcal | 2390.0 | 2404.3 | 2492.0 | 1969.0 | 1742.3 | 1933.7 | ||
| Number of steps (distance, km) | 5365 (3.9) | 4118 (3.0) | 5447 (4.0) | 1007 (0.7) | 975 (0.7) | 406. (0.3) | ||
| Time spent sedentary, min | 1192.5 | 1219.7 | 1045.0 | 1440.0 | 745.0 | 1245.3 | ||
| Time spent lightly active, min | 192.0 | 146.3 | 192.0 | 0.0 | 42.7 | 25.0 | ||
| Time spent fairly active, min | 9.5 | 39.3 | 18.7 | 0.0 | 0.0 | 0.0 | ||
| Time spent very active, min | 0.0 | 7.0 | 8.0 | 0.0 | 0.0 | 0.0 | ||
| Caloric expenditure with activity, kcal | 854.0 | 879.0 | 1006.3 | 0.0 | 159.7 | 100.0 | ||
| AKPS | 70 | 70 | 90 | 80 | 60 | 60 | 60 | 60 |
| EQ-5D-5L VAS | 57 | 75 | 60 | 60 | 60 | 65 | ||
| Sleep measures | ||||||||
| “How well did you sleep last night?” | Poorly | Moderately well | Moderately well | Moderately well | Moderately well | Very well | Very well | Very well |
| Epworth Sleepiness Scale | 11 | 11 | 13 | 2 | 7 | 3 | ||
| Leeds Sleep Questionnaire | ||||||||
| Getting to sleep | 31.3 | 55.0 | 48.0 | 47.0 | 50.0 | 77.3 | ||
| Quality of sleep | 40.5 | 65.0 | 49.5 | 48.0 | 51.0 | 64.0 | ||
| Waking in morning | 50.5 | 58.0 | 58.0 | 47.0 | 52.0 | 36.0 | ||
| Behaviour following waking | 72.0 | 63.7 | 55.3 | 50.7 | 53.3 | 51.3 | ||
| Constipation | Not at all | Severe | Not at all | Not at all | Not at all | Moderate | Mild | Mild |
| Global impression of change | Minimally improved | Very much improved | Very much improved | Much improved | Minimally improved | Much improved | ||
| Caregiver for participant 1 | Caregiver for participant 2 | |||||||
| Baseline | Week 1 | Week 3 | 6 months | Baseline | Week 1 | Week 3 | 6 months | |
| ZBI-12, 0–48 points | 29 | 26 | 6 | 12 | 0 | 0 | 0 | 0 |
SR: sustained-release; NRS: Numerical Rating Scale; mMRC: modified Medical Research Council scale; CRQ: Chronic Respiratory Disease Questionnaire; AKPS: Australian Karnofsy Performance Status; VAS: visual analogue scale; ZBI-12: Zarit Burden Interview. #: participant 1 was participant 2 in the qualitative study previously published [5]. ¶: participant 2 was participant 6 in the qualitative study previously published [5]. +: baseline values are mean scores across 2 days; week 1 and 3 values are mean scores of the last 3 days of each week (corresponding to morphine steady-state plasma concentrations).